Advanced

Urinary osteocalcin and other markers of bone metabolism: the effect of risedronate therapy

Kumm, Jaanika; Ivaska, Kaisa LU ; Rohtla, Kadri; Vaananena, Kalervo and Tamm, Agu (2008) In Scandinavian Journal of Clinical & Laboratory Investigation 68(6). p.459-463
Abstract
Objective. Serum osteocalcin (S-OC) is widely used as an index of bone formation. However, there is evidence that some urinary fragments of OC reflect resorption and might be useful in monitoring antiresorptive therapy. Here, we report 6-month changes in urinary midfragments of osteocalcin (U-MidOC) and other bone turnover markers in response to risedronate treatment. Material and methods. The study group comprised 19 patients with postmenopausal osteoporosis, aged 49-66 years, and receiving risedronate therapy. Fifty-four premenopausal women served as controls. Osteoporosis was diagnosed by lumbal bone mineral density (BMD). Urinary osteocalcin was measured by the U-MidOC assay for midfragments. Bone formation was assessed by S-PINP and... (More)
Objective. Serum osteocalcin (S-OC) is widely used as an index of bone formation. However, there is evidence that some urinary fragments of OC reflect resorption and might be useful in monitoring antiresorptive therapy. Here, we report 6-month changes in urinary midfragments of osteocalcin (U-MidOC) and other bone turnover markers in response to risedronate treatment. Material and methods. The study group comprised 19 patients with postmenopausal osteoporosis, aged 49-66 years, and receiving risedronate therapy. Fifty-four premenopausal women served as controls. Osteoporosis was diagnosed by lumbal bone mineral density (BMD). Urinary osteocalcin was measured by the U-MidOC assay for midfragments. Bone formation was assessed by S-PINP and S-OC, and resorption by S-CTx-I. Results. At baseline, U-MidOC was significantly correlated only with S-OC. After the 1st month of therapy, a similar decrease was observed in the values of U-MidOC and S-CTx-I, but in formation markers S-P1NP and S-OC only after three months. The rapid decrease in U-MidOC, analogous to S-CTX-I, and the different kinetics for urinary and serum OC suggest that urinary OC midfragments are more associated with resorption than S-OC. An association was also observed between the 1-month change in U-MidOC and 12-month gain in lumbar BMD. The response in U-MidOC after only the 1st month of therapy makes it a potential marker for monitoring the effect of risedronate, presumably reflecting different aspects of bone resorption than S-CTx-I does. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
postmenopause, osteoporosis, bone mineral density, antiresorptive therapy, bone markers
in
Scandinavian Journal of Clinical & Laboratory Investigation
volume
68
issue
6
pages
459 - 463
publisher
Informa Healthcare
external identifiers
  • wos:000259600100004
  • scopus:52949109136
ISSN
1502-7686
DOI
10.1080/00365510701832237
language
English
LU publication?
yes
id
cc1834c5-b101-4980-82ca-e855ba27895b (old id 1286958)
date added to LUP
2009-01-28 10:58:57
date last changed
2017-08-20 03:59:10
@article{cc1834c5-b101-4980-82ca-e855ba27895b,
  abstract     = {Objective. Serum osteocalcin (S-OC) is widely used as an index of bone formation. However, there is evidence that some urinary fragments of OC reflect resorption and might be useful in monitoring antiresorptive therapy. Here, we report 6-month changes in urinary midfragments of osteocalcin (U-MidOC) and other bone turnover markers in response to risedronate treatment. Material and methods. The study group comprised 19 patients with postmenopausal osteoporosis, aged 49-66 years, and receiving risedronate therapy. Fifty-four premenopausal women served as controls. Osteoporosis was diagnosed by lumbal bone mineral density (BMD). Urinary osteocalcin was measured by the U-MidOC assay for midfragments. Bone formation was assessed by S-PINP and S-OC, and resorption by S-CTx-I. Results. At baseline, U-MidOC was significantly correlated only with S-OC. After the 1st month of therapy, a similar decrease was observed in the values of U-MidOC and S-CTx-I, but in formation markers S-P1NP and S-OC only after three months. The rapid decrease in U-MidOC, analogous to S-CTX-I, and the different kinetics for urinary and serum OC suggest that urinary OC midfragments are more associated with resorption than S-OC. An association was also observed between the 1-month change in U-MidOC and 12-month gain in lumbar BMD. The response in U-MidOC after only the 1st month of therapy makes it a potential marker for monitoring the effect of risedronate, presumably reflecting different aspects of bone resorption than S-CTx-I does.},
  author       = {Kumm, Jaanika and Ivaska, Kaisa and Rohtla, Kadri and Vaananena, Kalervo and Tamm, Agu},
  issn         = {1502-7686},
  keyword      = {postmenopause,osteoporosis,bone mineral density,antiresorptive therapy,bone markers},
  language     = {eng},
  number       = {6},
  pages        = {459--463},
  publisher    = {Informa Healthcare},
  series       = {Scandinavian Journal of Clinical & Laboratory Investigation},
  title        = {Urinary osteocalcin and other markers of bone metabolism: the effect of risedronate therapy},
  url          = {http://dx.doi.org/10.1080/00365510701832237},
  volume       = {68},
  year         = {2008},
}